Related Experiment Video
Updated: May 7, 2026

Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats
Satoshi Maeda1, Sho-ichi Yamagishi, Takanori Matsui
1Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan.
Background/Aims:
Vildagliptin is an oral inhibitor of dipeptidyl peptidase-4, an enzyme mainly responsible for inactivating incretins, and one of the widely used drugs for the treatment of type 2 diabetes. However, effects of vildagliptin on retinal injury in diabetes remain unclear. We examined here whether oral administration of vildagliptin inhibited gene expression of inflammatory and thrombogenic parameters in Otsuka Long-Evans Tokushima Fatty rats (OLETF rats), an animal model of obese type 2 diabetes.
Methods:
OLETF rats at 22 weeks of age were given vehicle or 3 mg/kg of vildagliptin for another 10 weeks. Gene expression was analyzed in quantitative real-time reverse transcription-polymerase chain reaction.
Results:
Vildagliptin significantly inhibited the increase in body weight and decreased average fasting blood glucose in the OLETF rats. Compared with 22-week-old OLETF rats, gene expression levels of vascular endothelial growth factor, intercellular adhesion molecule-1, plasminogen activator inhibitor-1 and pigment epithelium-derived factor were significantly increased in the retinas of OLETF rats at 32 weeks of age, all of which were inhibited by treatment with vildagliptin.
Conclusions:
The present study demonstrated for the first time that vildagliptin inhibited inflammatory and thrombogenic reactions in the retinas of obese type 2 diabetic rats. Vildagliptin may play a protective role against diabetic retinopathy.
Related Concept Videos
Diabetic Retinopathy
Type II Diabetes II: Pathophysiology
Dipeptidyl Peptidase 4 Inhibitors
Type I Diabetes II: Pathophysiology
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational

